Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.70 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.61 |
| ▸ | KDM1A | O60341 | 1/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28864249 | 0.98 | HDAC1 (0.68) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL8113734 | 0.94 | HDAC1 (0.69) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL29263701 | 0.93 | HDAC1 (0.72) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL967387 | 0.88 | HDAC2 (0.68) | HDAC1HDAC2HDAC8HDAC6SMN1; SMN2 | |
| SCHEMBL722568 | 0.87 | HDAC1 (0.55) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL562849 | 0.86 | HDAC1 (0.54) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL4112338 | 0.83 | TRPV1 (0.59) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL18893638 | 0.83 | HDAC1 (0.50) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| Phenylbutyrylhydroxamic Acid SCHEMBL1350853 | 0.82 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL7814720 | 0.81 | CYP1A2 (0.48) | HDAC1HDAC2HDAC3HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1272456-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | claimed |
| WO-2001079157-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-25 | — | — | WO | claimed |
| US-20250288559-A1 | PREP BINDING LIGANDS | POLKU THERAPEUTICS OY (FI) | 2025-09-18 | — | — | US | disclosed |
| EP-4514781-A1 | PREP BINDING LIGANDS | Polku Therapeutics OY (FI) | 2025-03-05 | — | — | EP | disclosed |
| CN-119451944-A | PREP binding ligands | 珀尔库治疗有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2023209191-A1 | PREP BINDING LIGANDS | UNIVERSITY OF HELSINKI (FI) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023209191-A1 | PREP BINDING LIGANDS | UNIVERSITY OF HELSINKI (FI) | 2023-11-02 | — | — | WO | disclosed |
| US-9845323-B2 | 2-(1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1 ]octane derivatives and their use as antibacterial agents | WOCKHARDT LIMITED (IN) | 2017-12-19 | — | — | US | disclosed |
| US-9845323-B2 | 2-(1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1 ]octane derivatives and their use as antibacterial agents | WOCKHARDT LIMITED (IN) | 2017-12-19 | — | — | US | disclosed |
| US-9822115-B2 | Nitrogen containing compounds and their use as antibacterial agents | WOCKHARDT LIMITED (IN) | 2017-11-21 | — | — | US | disclosed |
| US-9822115-B2 | Nitrogen containing compounds and their use as antibacterial agents | WOCKHARDT LIMITED (IN) | 2017-11-21 | — | — | US | disclosed |
| US-20140107166-A1 | HISTONE DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| WO-2013000108-A1 | AZOLE HETEROCYLIC COMPOUNDS, PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | 中国科学院上海药物研究所 (CN) | 2013-01-03 | — | — | WO | disclosed |
| WO-2012112447-A9 | HISTONE DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012112447-A2 | HISTONE DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
| EP-1335908-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | LILLY CO ELI (US) | 2008-02-13 | — | — | EP | disclosed |
| CN-101087771-A | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds | PFIZER (US) | 2007-12-12 | — | — | CN | disclosed |
| EP-1272456-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
| WO-2001079157-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107166-A1 | HISTONE DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC1, HDAC5, HDAC11 | HDAC1 1/4885HDAC2 4/4885HDAC3 9/4885 |
| US-20250288559-A1 | PREP BINDING LIGANDS | PREP, ERAP2, CTSA | HDAC1 287/4885HDAC2 295/4885HDAC3 279/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | HDAC1 356/4885HDAC2 521/4885HDAC3 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.